Metabolomics strategy for diagnosing urinary tract infections

Daniel B. Gregson[1,2]†, Spencer D. Wildman[3]†, Carly C.Y. Chan[3]†, Dominique G. Bihan[3], Ryan A. Groves[3], Raied Aburashed[3] Thomas Rydzak[3], Keir Pittman[3], Nicolas Van Bavel[3], and Ian A. Lewis[3]*

[1] Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, T2N 1N4, Canada

[2] Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, T2N 1N4, Canada

[3] Alberta Centre for Advanced Diagnostics, Department of Biological Science, University of Calgary, Calgary, AB, T2N 1N4, Canada

† Equal contributions

*Corresponding author: Ian A. Lewis

Department of Biological Sciences
2500 University Drive NW
Calgary, AB, Canada T2N 1N4
1-403-220-4366
ian.lewis2@ucalgary.ca

Abstract

Metabolomics has emerged as a mainstream approach for investigating complex metabolic phenotypes but has yet to be integrated into routine clinical diagnostics. Metabolomics-based diagnosis of urinary tract infections (UTIs) is a logical application of this technology since microbial waste products are concentrated in the bladder and thus could be suitable markers of infection. We conducted an untargeted metabolomics screen of clinical specimens from patients with suspected UTIs and identified two metabolites, agmatine and N6-methyladenine, that are predictive of culture positive samples. We developed a 3.2-minute LC-MS assay to quantify these metabolites and showed that agmatine and N6-methyladenine correctly identify UTIs caused by 13 *Enterobacterales* species and 3 non-*Enterobacterales* species, accounting for over 90% of infections (agmatine AUC > 0.95; N6-methyladenine AUC > 0.89). These markers were robust predictors across two blinded cohorts totaling 1,629 patient samples. These findings demonstrate the potential utility of metabolomics in clinical diagnostics for rapidly detecting UTIs.

52 **Main Text**

53 **Introduction**

54 Infections are caused by a wide range of microbes that, like all organisms, consume nutrients
55 and secrete metabolic waste products. These microbial metabolites can be highly abundant at the
56 site of infection[1] and thus, could potentially serve as targets for a metabolism-based diagnostic
57 strategy. Urinary tract infections (UTIs) are particularly amenable to this metabolic diagnostic
58 approach because microbial metabolites are concentrated in the bladder and can be easily detected
59 by liquid chromatography mass spectrometry (LC-MS) analysis of patient urine. *Escherichia coli*,
60 the most common UTI pathogen, produces a variety of diamines, polyamines, and acylated
61 conjugates of these molecules that are not typically found in human urine. These molecules have
62 been reported as potential UTI biomarkers for over three decades[2,3], with more recent work
63 suggesting that these amine-linked molecules may play a role in resistance to nitrosative stress in
64 the bladder[4,5].

65 Although microbial metabolites have been recognized as potential diagnostic targets, they have
66 yet to be translated into a clinical diagnostic tool. The reason for this is threefold: 1) concentrations
67 of the microbial polyamines are quite variable in urine[6] and are thus of borderline utility for
68 diagnostic purposes, 2) only biomarkers of *E. coli* have been reported thus far, which is problematic
69 because it is only one of many UTI-causing organisms[7], and 3) LC-MS has only recently become
70 sufficiently robust to serve as a practical diagnostic platform. The primary objective of this study
71 was to conduct a systematic analysis of microbial metabolites found in urine from symptomatic
72 UTI patients to identify any molecules with sufficient predictive power to enable rapid, metabolic-
73 based diagnostics. Using an untargeted LC-MS metabolomics approach, we identified two novel
74 biomarkers that report on a wide transect of UTI pathogens. We then assess the potential utility of
75 metabolomics-based UTI screening in two blinded cohorts totaling 1,629 urine samples.

Results

UTI biomarker discovery

UTIs are diagnosed based on patient symptoms supported by laboratory diagnostic tests. These clinical tests include culturing urine specimens for 18 hours to identify patients with significant bacteriuria (defined by Alberta Precision Laboratories guidelines as specimens with $>10^7$ CFU/L)[8]. Microbial catabolites present in the urine could potentially provide a culture-independent mechanism for rapidly identifying these positive samples. To identify potential biomarkers in these urine specimens, untargeted metabolomics analyses (Figure 1a; Supporting Dataset 1) of 77 culture-positive urine samples and 33 culture negative samples ($<10^7$ CFU/L)—all collected from symptomatic patients—were conducted using LC-MS. The most diagnostic features in this dataset, as judged by area under the curve (AUC) of the receiver operating characteristic (ROC) curve, were m/z 114.1025 (AUC=0.98), m/z 131.1289 (AUC=0.89), and m/z 150.0772 (AUC= 0.91; Figure 1b; Supporting Dataset 1). The first two of these untargeted signals were putatively assigned to agmatine, a product of arginine metabolism[9], and the third was assigned to N6-methyladenine, a modified nucleobase found in prokaryotes[10]. These assignments were validated by LC-MS/MS fragmentation patterns as well as co-elution of the target signal with analytical standards (Figure 1c,d).

Validation of agmatine as a UTI biomarker

Although both agmatine and N6-methyladenine were predictive of positive urine cultures, the levels of these metabolites were not uniform across UTI-causing pathogens. Infections caused by the most prominent UTI-causing *Enterobacterales* species, such as *E. coli*, were associated with elevated agmatine, whereas N6-methyladenine levels were elevated in infections caused by a small number of non-*Enterobacterales* species (Supporting Dataset 1). To better understand these species-specific phenotypes, the performance of agmatine was assessed using 519 urine cultures that were taken directly from a clinical diagnostic pipeline. Stable isotope labeled [U-^{13}C]agmatine

101 was spiked into samples, samples were purified using solid phase extraction (SPE) on a silica
102 column, and agmatine and [U-^{13}C]agmatine levels were measured using a targeted mass
103 spectrometry method. Agmatine concentrations were thus quantifiable based on the signal ratio
104 between isotope-labeled and native species. As expected, urinary agmatine levels were closely
105 correlated with the presence of uropathogenic *Enterobacterales*, whereas culture-negative urine
106 samples contained no detectable agmatine (AUC of 0.99, CI of 0.98 - 1.00; Fig 2a; Supporting
107 Dataset 2). Moreover, we found that a diagnostic threshold of 174 nM agmatine was predictive of
108 infections caused by *E. coli*, *Citrobacter* species, *Enterobacter* species, *Klebsiella* species, and
109 *Proteus mirabilis* (sensitivity, 94%; specificity, 97%; PPV, 0.96; NPV, 0.95; Figure 2a), all of
110 which showed significantly higher agmatine levels than urine from culture negative patients (p =
111 2.15×10^{-45}, $p = 1.43\times10^{-49}$, $p = 2.22\times10^{-52}$, $p = 3.85\times10^{-40}$, $p = 5.91\times10^{-47}$, respectively via two-tail
112 unequal variance Welch T-test relative to culture negative urine samples; Supporting Dataset 2).

113 *Validation of N6-methyladenine as a UTI biomarker*

114 Although the agmatine-based screening approach captures most UTI infections caused by
115 *Enterobacterales* species—which collectively account for >83% of UTIs[7]—it did not capture those
116 caused by enterococci, staphylococci, or other less common species (e.g Group B strep,
117 *Pseudomonas aeruginosa*, *Aerococcus urinae*, *Candida albicans*). Since these pathogens account
118 for a small percentage of all UTIs, we prospectively collected a targeted cohort of 71 non-
119 *Enterobacterales* UTI specimens along with 24 negative controls. LC-MS analyses showed that
120 N6-methyladenine signals correctly differentiated culture-negative urine samples from this selected
121 cohort of infections (sensitivity, 91%; specificity, 83%; PPV, 0.84; NPV, 0.91; Figure 2b;
122 Supporting Dataset 3). However, there were clear species-to-species differences in the quality of
123 these metabolic diagnostics, with *Staphylococcus aureus*, *Staphylococcus saprophyticus*, and
124 *Aerococcus urinae* showing the most significant differences after Bonferroni correction from
125 multiple hypothesis testing ($p = 1.26\times10^{-3}$, $p = 3.22\times10^{-4}$, $p = 3.72\times10^{-6}$, respectively via two-tail

126 unequal variance Welch T-test relative to culture negative urine samples; Figure 2b; Supporting
127 Dataset 4). N6-methyladenine levels were predictive of these three non-*Enterobacterales* species
128 (AUC of 0.80; CI, 0.69 – 0.92; Supporting Dataset 3). N6-methyladenine is part of a wider family
129 of adenine derivatives, including 1-methyladenine and adenine, which were elevated in the urine
130 of these UTI patients (Supporting Dataset 4). However, our LC-MS analyses showed that the
131 diagnostic performance of these additional markers was lower, and these compounds were linked
132 to fewer species than N6-methyladenine.

133 *Validation of microbial metabolic capacity*

134 Agmatine and N6-methyladenine in the urine of UTI patients could potentially originate from
135 microbial or human metabolism. To better understand the origin of these molecules, filter sterilized
136 urine was taken from healthy controls and was inoculated with *E. coli* and *S. aureus* isolates. In the
137 case of the *E. coli* culture, 20 μM of ^{15}N-labelled arginine (a physiologically relevant level
138 approximating the concentration of native urinary arginine) was added to the urine at the start of
139 the incubation. Throughout the incubation, isotope-labeled arginine levels progressively decreased
140 while isotope-labeled agmatine was produced (Figure 2c). The appearance of isotope-labeled
141 agmatine is expected under these conditions due to the microbial arginine decarboxylase activity
142 of *E. coli*[9]. Likewise, we screened the *S. aureus* cultures over 12 hours via LC-MS and observed
143 that N6-methyladenine was produced by these microbes when grown in filter-sterilized urine
144 (Figure 2c). In summary, the most diagnostic biomarkers observed in UTI specimens are readily
145 produced by UTI pathogens grown in filter-sterilized urine, indicating that these metabolites are
146 naturally produced through microbial metabolic activity.

147 Urine specimens for UTI diagnostics are generally collected in outpatient clinics and delivered
148 to centralized microbiology testing labs. Sample transport logistics and other delays in analysis
149 could therefore complicate microbial diagnostics if microbes were allowed to grow. To control this,
150 urine specimens are collected in boric acid tubes, which inhibit microbial growth. To verify that

151 microbes stored in boric acid tubes will not produce our target metabolites, which could cause false
152 positive results in specimens with sub-clinical bacterial levels (< 10^7 CFU/L), we screened for
153 agmatine production in three reference strains of *E. coli* and four clinical isolates, in boric acid over
154 24 hours via LC-MS. In the absence of boric acid preservatives, agmatine levels reached a peak
155 intensity after 7 hours and maintained elevated levels over the next 17 hours (Supplementary Figure
156 1a). In contrast, isolates stored in boric acid preservatives did not produce agmatine over the 24-
157 hour period (Supplementary Figure 1b).

158 *Clinical Cohort 1*

159 Although untargeted metabolomics is currently not used for clinical diagnostics, mass
160 spectrometry is a routine component of many diagnostic labs where it serves as a platform for
161 quantifying a range of biomolecules including steroid hormones, drugs of abuse, and metabolites
162 that are linked to inborn errors of metabolism[11]. Consequently, much of the requisite infrastructure
163 necessary for diagnosing UTIs via metabolic profiles can be found in diagnostic laboratories.
164 However, the instrumentation used for untargeted metabolomics analyses is quite different from
165 that employed in clinical settings. To demonstrate the feasibility of adapting our metabolomics
166 approach to routine clinical diagnostics, we developed a targeted diagnostics workflow using a
167 triple quadrupole LC-MS instrument that is commonly used for clinical mass spectrometry.

168 To determine the performance of this clinically-adapted UTI diagnostics approach, we
169 conducted a head-to-head performance evaluation of our LC-MS method versus results obtained
170 via the traditional clinical microbiology approach[12]. This cohort consisted of 587 urine specimens
171 submitted to Alberta Precision Laboratories (South Hub) over a 48-hour period. The demographics
172 of these specimens have been described previously[7]. Briefly, these samples were taken from the
173 greater Calgary metropolitan area where 74% of urine cultures are submitted from ambulatory out-
174 patient visits, 18% from hospitalized patients, and 9% from nursing home residents. Females have
175 a 6-fold higher incidence rate of UTIs than males in this population. Importantly, Alberta follows

176 the "Choosing Wisely Canada" guidelines wherein physicians are instructed to only submit urine
177 cultures from symptomatic patients[13]. This head-to-head trial confirmed our previous results: urine
178 agmatine levels correctly predicted *Enterobacterales* infections (Figure 3, AUC of 0.96; CI of 0.94
179 – 0.98). Moreover, at the previously determined agmatine threshold of 174 nM, LC-MS diagnostics
180 had a 95% sensitivity and 86% specificity for predicting *Enterobacterales* infections (Figure 3,
181 Supporting Dataset 5). As expected, our culture-negative samples, those classified as being of
182 doubtful clinical significance (DCS; $<10^7$ CFU/L), and a small number of urine samples (<5%)
183 containing non-*Enterobacterales* microbes all had agmatine levels below the limit of detection.
184
185 *Clinical Cohort 2*
186 One limitation of our original targeted method is that it was specific to agmatine and thus could
187 not be expanded to the analysis of other urinary metabolites, including creatinine, a standard marker
188 of urinary dilution[14,15]. To address this limitation, we developed a "dilute and shoot" sample
189 preparation workflow coupled with a 3.2-minute LC-MS targeted assay for agmatine, N6-
190 methyladenine, and creatinine. To enable accurate quantification of agmatine/N6-methyladenine
191 and creatinine, which are present at substantially different concentrations in urine (nM versus mM),
192 we used a higher dilution (1:200 final) than in the previous trial. Using this assay, we analyzed
193 1,042 urine specimens from suspect UTI cases. In this cohort, we again showed that urinary
194 agmatine concentrations over 174 nM is an accurate predictor of *Enterobacterales* infections (93%
195 sensitivity; 90% specificity; PPV, 0.67; NPV, 0.98; Figure 4, Supporting Dataset 6). Moreover, we
196 showed that creatinine normalization had a slight negative impact on the performance of the assay
197 (AUC of 0.95, CI 0.93-0.97; versus 0.92, CI 0.89-0.95; for agmatine alone versus creatinine-
198 normalized agmatine levels, respectively; Figure 4, Supplemental Dataset 6). N6-methlyadenine
199 levels were also found to be predictive of UTIs (AUC of 0.71, CI 0.69 – 0.74; inclusive of all
200 species; Supplemental Dataset 6). As expected, the performance of N6-methlyadenine was

201 improved when analyses were restricted to the three known N6-methlyadenine producing species
202 (AUC, 0.89; CI, 0.75 - 1.0; Supporting Dataset 6, Supplementary Figure 2). In this restricted sub-
203 cohort, a N6-methlyadenine concentration of 217 nM had a sensitivity of 0.78 and specificity of
204 0.79 for differentiating infections with *S. aureus*, *S. saprophyticus*, and *A. urinae* versus infections
205 with all other species and negative specimens (Supplementary Figure 2, Supporting Dataset 6). We
206 also tested the performance of a composite model using both agmatine and N6-methlyadenine
207 levels to predict infections. This combined model performed slightly worse than the agmatine-only
208 model as a generalized tool for detecting UTIs (inclusive of all species, AUC of 0.85 versus 0.78
209 for the composite versus agmatine-only models, respectively; Supporting Dataset 6).
210

211 **Discussion**

212 UTIs are one of the most common bacterial infections and are responsible for over eight
213 million healthcare visits per year in the U.S. alone[16,17]. As a result, urine cultures are one of the
214 most common tests performed by microbiology reference labs (24–40% of all cultures analyzed)[18].
215 The current diagnostic workflow used to process these samples follows a multi-day procedure that
216 includes: streaking urines on agar plates, incubation for 18 hours, colony counting, microbial
217 identification via MALDI-TOF mass spectrometry, and antibiotic susceptibility testing[12]. This long
218 diagnostic workflow (24–48 hours) encourages clinicians to prescribe antibiotics before lab results
219 are available. Given that up to 70% of suspected UTI cases collected by clinical testing facilities
220 are ultimately found to be culture negative, the current empiric antimicrobial prescribing practice
221 leads to overprescribing and may contribute to the spread of antimicrobial resistance[19–21].
222 Therefore, rapid diagnostic tools that can quickly identify patients with UTIs could enable more
223 precise antimicrobial prescribing practices[22–24].

224 Herein, we used untargeted metabolomics to identify native biomarkers present in uncultured
225 urine that robustly differentiate between culture negative and culture positive patients. Using these

226 untargeted data, we identified two predictive metabolites (agmatine and N6-methyladenine) that
227 are elevated in uncultured urine from patients who were later confirmed to have UTIs. We show
228 that these biomarkers are produced by UTI pathogens when they are cultured in urine and that an
229 agmatine concentration of 174 nM and N6-methyladenine concentration of 217 nM in urine
230 corresponds with the clinical definition of bacteriuria (>10^7 CFU/L)[8]. We developed a clinical LC-
231 MS workflow to detect these molecules and demonstrated that these biomarkers are robust
232 predictors of UTIs in two independent cohorts consisting of 1,629 clinical specimens in total (AUC
233 > 0.95 and 0.89 for 13 *Enterobacterales* and 3 non-*Enterobacterales* species, respectively).
234 Collectively, these data show that metabolite levels present in uncultured urine can be used to
235 accurately reproduce the results generated by traditional urine culture and, therefore, could
236 potentially enable novel rapid UTI testing approaches.

237 The multiple independent trials we conducted over the course of this study provide some
238 insights into leveraging metabolite biomarkers of UTIs. Firstly, our creatinine normalization study
239 showed that correcting metabolite levels to account for variability in urinary dilution does not
240 improve their diagnostic performance – if anything these corrections make things worse (Figure 4;
241 Supporting Dataset 6). This observation is consistent with our microbial culturing experiments,
242 which showed that agmatine and N6-methyladenine are normal microbial catabolites produced
243 when UTI pathogens are grown in urine. Thus, if agmatine and N6-methyladenine levels in patient
244 samples primarily result from microbial metabolism within the urinary tract, we would expect both
245 the biomarker levels and planktonic bacterial density in the urine (in CFU/L) to be diluted in
246 parallel. Given that the clinical definition of bacteriuria is based on bacterial density[8] it is
247 unsurprising that the microbially-produced catabolites we identified were most diagnostically
248 robust when their levels were not corrected for urinary dilution. This observation has practical
249 implications: quantifying the abundant creatinine necessitated a higher dilution than is necessary
250 for quantifying the low-abundant agmatine and N6-methyladenine. This over-dilution diminished

251 the performance of our target markers in our final clinical cohort, as their signals were closer to the
252 LC-MS noise threshold. Thus, omitting creatinine normalization improves performance of our
253 assay.

254 Another practical observation from our final clinical cohort is that a mixed agmatine/N6-
255 methyladenine model for predicting infection performed slightly worse than an agmatine only
256 model (all cause UTI; mixed AUC 0.78, 0.74-0.81; agmatine only AUC 0.85, 0.82-0.88; Supporting
257 Dataset 6). The reason for this is that only 9 out of the 1,042 urine specimens (9 out of 277 positive
258 samples; 3.2%) in the final cohort were from infections with N6-methyladenine-producing
259 organisms. This prevalence is consistent with previous studies in the same region (3.2% vs 2.1%)[7].
260 Thus, screening samples via N6-methyladenine levels added false discovery, but minimal
261 additional sensitivity to the assay. This is a common problem in screening for rare events[25] and
262 suggests that an agmatine-only screening approach might be preferable.

263 One important consideration about the generalizability of our findings is that the mix of species
264 observed in clinical specimens will have a direct impact on the clinical performance of our
265 biomarker-based diagnostic approach. The proportions of species we observed are largely
266 consistent with those reported elsewhere with the exception of *S. saprophyticus* (an N6-
267 methyladenine-producer), which was underrepresented relative to the North American average (1%
268 vs 5%)[26,27]. Therefore, N6-methyladenine could potentially be of greater diagnostic value in other
269 health jurisdictions – especially in jurisdictions with a greater proportion of out-patient cases.

270 The robust performance of agmatine as a diagnostic marker for *Enterobacterales* infections
271 across four separate cohorts suggests that this metabolite is a good candidate for clinical
272 applications. As an LC-MS assay, agmatine screening could be used to rapidly identify patients
273 with clinically significant bacteriuria. This screening approach is 18 hours faster than the traditional
274 urine culture workflow and could accommodate thousands of analyses per day[28]. Alternatively,
275 agmatine screening for UTIs could also be enabled via point-of-care testing tools, such as lateral

flow assays, which could be made possible via existing commercial antibodies for agmatine[29]. If such a point-of-care tool were made, it would complement existing dipstick-style UTI screening tests (i.e. nitrate and leucocyte esterase)[30]. In this context, agmatine screening would be both favorable from a performance perspective (Supporting Dataset 7) and because the *Enterobacterales*-specific agmatine test could be used to help guide more precise prescribing decisions.

Although we demonstrate robust performance of our metabolomics-based UTI screening concept, there are some important limitations of this strategy that warrant discussion. Firstly, the biomarkers we identify here report bacteriuria (high levels of bacteria in the urine), not infection. This distinction is important as asymptomatic bacteriuria is common and does not necessarily warrant antimicrobial therapy[31]. Thus, agmatine/N6-methaladenine screening would need to be paired with symptomatic evaluation by a clinician to enable UTI diagnosis (i.e. following existing practice). Secondly, the gold-standard diagnostic workflow involves both species-level identification of the pathogen and empiric antimicrobial susceptibility testing, neither of which is possible with our screening approach alone. However, most UTIs are treated without supporting lab data. Therefore, we envision agmatine/N6-methaladenine screening as a tool to improve empiric prescribing practices rather than as a replacement for culture-based diagnostics. Thirdly, the biomarkers we report here have clinically significant blind spots, especially in the context of UTIs from hospitalised patients. New biomarkers covering *Candida*, *Enterococcus, Pseudomonas,* and group B *Streptococcus* must be identified if our proposed metabolism-based UTI screening concept is to be applied to hospitalized patients. Despite these limitations, the agmatine/N6-methaladenine screening approach we introduce here is robust, reproducible over multiple independent clinical cohorts, and could add significant value as a point-of-care or patient-near tool to enable more precise empiric prescribing decisions for uncomplicated UTIs.

301

302 **Methods**

303 *Experimental design*

304 Untargeted analysis for biomarker discovery was performed directly on patient urine samples
305 (77 culture positive, 33 culture negative) using a Q Exactive™ HF Hybrid Quadrupole-Orbitrap™
306 Mass Spectrometer. Putative biomarkers were identified using MS/MS analysis and matched to
307 standards using fragmentation spectra and retention times. To identify agmatine thresholds that
308 differentiate culture positive ($\geq 10^7$ CFU/L; n=240) versus culture negative urines ($<10^7$ CFU/L;
309 n=279), patient urines were spiked with a known concentration of labeled [U-^{13}C]agmatine,
310 purified using solid phase extraction (SPE), and analyzed on the TSQ Quantum™ Access MAX
311 Triple Quadrupole Mass Spectrometer. Agmatine concentrations were quantified based on the
312 signal ratio between isotope-labeled and native species. Quantitative analyses of N6-methyladenine
313 were performed directly on patient urine samples (71 culture positive non-*Enterobacterales*, 24
314 culture negative) using external standards following analysis via the Q Exactive™ HF platform. To
315 demonstrate that agmatine and N6-methyladenine originate from microbial metabolism, *E. coli* and
316 *S. aureus* were incubated in sterilized urine and production of biomarkers was monitored. Similarly,
317 to demonstrate that agmatine concentrations are proportional to microbial load, Mueller Hinton
318 Medium was seeded with varying concentrations of *E. coli* (10^3-10^8 CFU/mL) and agmatine levels
319 were measured following a 6-hour incubation period. Inhibition of agmatine production by boric
320 acid was also monitored in filter sterilized urine seeded with *E. coli* during a 24-hour incubation
321 period. Two clinical trials were performed to validate discovered biomarkers. The first clinical trial
322 was performed using SPE purified urine samples (n=587) on the TSQ Quantum™. In the second
323 clinical trial (dilute and shoot approach), methods were developed to quantify agmatine, N6-
324 methyladenine, and creatinine directly in urine using a single injection. For these analyses, urine

325 from residual clinical urine samples (n=1,042) was analyzed after a 1:200 dilution (V:V in 50%
326 methanol final) using the TSQ Altis™ triple quadrupole. The specific LC-MS methods for each
327 experiment are described below.

328 *Urine sample collection*

329 Mid-stream urine samples were collected from Alberta Precision Laboratories' (APL)
330 standardized urine analysis workflow, consisting of samples submitted for urine culture from
331 symptomatic ambulatory (74%), hospitalized (18%), and nursing home patients (9%) in the Calgary
332 metropolitan area. Age demographics are divided as follows: 20/1,000 for ages <1; <20/1,000 for
333 ages 1-59; 24/1,000 for ages 60-69; 32/1,000 for ages 70-79; 100/1,000 for ages 80-89; 851/1,000
334 for ages >90. Incidence rates in females are 30/1,000 and males are 5/1,000. Samples were de-
335 identified prior to transfer to the study team. In brief, urine was plated either manually with a loop
336 or using automated equipment onto UriSelect™ Media (Bio-Rad, Canada) and incubated
337 aerobically for 18 hours. Growth of bacteria was enumerated as per standard recommendations[12]
338 and colonies present in significant quantities were speciated using the Vitek™ MS system
339 (bioMérieux, Canada). Residual samples from this standard diagnostic lab workflow were fixed
340 1:1 with 100% methanol within 48 hours post-receipt at APL, and then frozen at -80 °C. All samples
341 were thawed, centrifuged at 14,800 × g, and diluted ten-fold further into 50% HPLC-grade
342 methanol prior to LC-MS analysis. All samples were acquired under approval from Conjoint Health
343 Research Ethics Board certificate REB19-0442.

344 *Untargeted mass spectrometry*

345 Untargeted analysis of positive and negative urine samples was performed for UTI biomarker
346 discovery and quantification of N6-methyladenine thresholds. Methods were adapted from
347 previously published studies[32–37]. Briefly, metabolic analyses were performed on a Q Exactive™
348 HF Hybrid Quadrupole-Orbitrap™ Mass Spectrometer (Thermo-Fisher) coupled to a Vanquish™

349 UHPLC System (Thermo-Fisher). Chromatographic separation of metabolites was performed on
350 Syncronis HILIC UHPLC column (2.1mm x 100 mm x 1.7 µm, Thermo-Fisher) at a flow rate of
351 600 µL/min using a binary solvent system: solvent A, 20 mM ammonium formate pH 3.0 in mass
352 spectrometry grade H_2O and solvent B, mass spectrometry grade acetonitrile with 0.1% formic acid
353 (%v/v). For initial biomarker discovery experiments, the following 15-minute gradient was used:
354 0–2 min, 100% B; 2–7 min, 100–80% B; 7–10 min, 80–5% B; 10–12 min, 5% B; 12–13 min, 5–
355 100% B; 13–15 min, 100% B. The mass spectrometer was run in positive and negative full scan
356 mode at a resolution of 240,000 scanning from 50-750 m/z. Metabolite data were analyzed by El-
357 MAVEN software package[38,39]. Metabolites were identified by matching observed m/z signals (+/-
358 10 ppm) and chromatographic retention times to those observed from a commercial metabolite
359 library of standards (MSMLS; Sigma-Aldrich). Assignments were verified on the Thermo Fisher
360 Q Exactive™ HF platform via MS/MS fragmentation analysis and co-elution of standards with the
361 identified signals from urine.

362 *Targeted mass spectrometry*

363 Targeted mass spectrometry analysis for validation of agmatine as a UTI biomarker and clinical
364 trial 1 was performed on a TSQ Quantum™ Access MAX (Thermo Scientific). For quantitative
365 analyses the following transitions were monitored using a fixed collision energy of 15 eV: ^{12}C
366 agmatine, 131.2→72.4 m/z; [U-^{13}C]agmatine, 136.2→76.4 m/z in positive ionization mode. The
367 same HPLC column and buffers were used as described above, with the following modified 6-
368 minute gradient: 0–0.5 min, 100% B; 0.5–2 min, 100–5% B; 2–3.5 min, 5–0% B; 3.5–4.5 min, 0%
369 B; 4.5–5 min, 0–100% B; 5–6 min, 100% B. For targeted experiments using the TSQ Quantum™,
370 electrospray ionization source conditions were as follows: spray voltage of 3000 V, sheath gas of
371 25 (arbitrary units), auxiliary gas of 10 (arbitrary units), sweep gas of 0 (arbitrary units), capillary
372 temperature of 275 °C, auxiliary gas temperature of 325 °C.

373 *Dilute and shoot*

374 For clinical trial 2 ("dilute and shoot" approach), LC-MS/MS analysis was performed on a
375 Vanquish™ UHPLC system, with an integrated Vanquish™ charger module (Thermo Scientific),
376 coupled to a TSQ Altis™ triple quadrupole mass spectrometer (Thermo Scientific) equipped with
377 an electrospray ionization (HESI-II) probe. The UHPLC-MS platform was controlled by an
378 Xcalibur™ data system (Thermo Scientific). Chromatographic separation was achieved on a
379 Syncronis™ HILIC column (50 X 2.1 mm, 1.7 µm, Thermo Fisher Scientific) using a binary
380 solvent system composed of LC-MS grade H_2O with 20 mM ammonium formate, pH3 (solvent A)
381 and LC-MS grade acetonitrile with 0.1% (%v/v) formic acid (solvent B). The following 3.2 min
382 gradient was used: 0–0.5 min, 95% B; 0.5–1.75 min, 95-30% B; 1.75–1.8 min, 30-5% B; 1.8–2.3
383 min, 5% B; 2.3-2.4 min, 5-95% B; 2.4-3.2 min, 95% B. The flow rate was 1 mL min^{-1} and the
384 sample injection volume 2 µL. The auto sampler and charger were kept at 6 °C and the column at
385 30 °C. For quantitative analyses the following transitions were monitored using the following
386 polarities, collision energies and transitions: agmatine, positive, 16 eV, 131.0→97.1 m/z; N6-
387 methyladenine, positive, 23 eV, 150.0→122.9 m/z; creatinine, positive, 13 eV, 114.1→86.1 m/z.
388 Electrospray ionization source conditions were as follows: spray voltage of 3000 V (2500 V,
389 negative mode), vaporizer temperature of 250 °C, sheath gas of 35 (arbitrary units), auxiliary gas
390 flow of 15(arbitrary units) and sweep gas flow of 2 (arbitrary units), capillary temperature of 275
391 °C.

392 *Determination of agmatine threshold values using [U-^{13}C]agmatine*

393 Targeted quantitative analysis was conducted to establish agmatine thresholds between culture
394 positive and culture negative urine samples (Validation of agmatine as a UTI marker) and to assess
395 performance thresholds (Clinical cohort 1). Quantitative analyses of agmatine in 519 urine samples
396 was undertaken using a known concentration of a [U-^{13}C]agmatine isotope as an internal standard
397 in the urine sample (see [U-^{13}C]agmatine standard biosynthesis and purification below). Prior to
398 MS analysis, samples were purified using a solid phase extraction (SPE) 96-well HyperSep™ Silica

399 plate. Columns were equilibrated with methanol followed by water, then loaded with the sample of
400 interest. Columns were then washed with methanol, water, methanol with 0.1% formic acid, water
401 with 0.1% formic acid. The target analyte was eluted with water containing 2% formic acid. LC-
402 MS analysis was performed using a TSQ Quantum™ Access MAX Triple Quadrupole Mass
403 Spectrometer (Thermo Scientific). For the clinically-adapted blinded evaluation, clinical urine
404 specimens were centrifuged and the supernatant was spiked with the [U-^{13}C]agmatine isotope.
405 These samples were analyzed directly on a TSQ Quantum™ Access MAX instrument.
406

407 *[U-^{13}C]agmatine standard biosynthesis and purification*

408 *Escherichia coli* (strain MG1665) was seeded into M9 minimal media containing 22.2 mM [U-
409 ^{13}C]glucose, grown overnight, and was then seeded into fresh [U-^{13}C]glucose-containing media.
410 This culture was then incubated under agitation in a 37 °C, 5% CO_2 incubator. Glucose
411 consumption was monitored using a blood glucose monitoring system (Bayer Contour Next). When
412 glucose levels in the media reached 5 mM, the culture was centrifuged, the supernatant was
413 retrieved, was adjusted to pH 7 with ammonium bicarbonate, and was steri-filtered. [U-
414 ^{13}C]agmatine was isolated and purified using a solid phase extraction column (HyperSep™ Silica
415 Cartridges, # 60108-712, Thermo Scientific), as described above and scaled accordingly to the
416 column volume. The fraction was concentrated to 1/10th of its initial volume in a vacuum
417 concentrator at 4 °C and labeled [U-^{13}C]agmatine in the final sample was quantified by stable
418 isotope dilution via LC-MS/MS using an unlabeled internal standard curve.

419 *Validation of microbial metabolic capacity*

420 *E. coli* and *S. aureus* were inoculated in sterilized urine to verify that agmatine and N6-
421 methyladenine originate from microbial metabolism. *In vitro* microbial samples were cultured from
422 reference strains of bacteria (*E. coli*: MG1665, ATCC 25922, ESBL ATCC BAA-196; *S. aureus*:
423 ATCC25923, ATCC 43300 (MRSA)). Briefly, cryogenic stocks were grown overnight in Mueller-

424 Hinton medium, then inoculated at 10^5 CFU/mL in sterilized urine and grown at 37 °C. *E. coli*
425 cultures were spiked with [guanido-$^{15}N_2$]arginine (herein referred to as "[$^{15}N_2$]arginine") such that
426 the urine contained an approximate 1:1 ^{12}C arginine to [$^{15}N_2$]arginine ratio. The disappearance of
427 [$^{15}N_2$]-arginine and appearance of [guanido-$^{15}N_2$]agmatine (herein referred to as "[$^{15}N_2$]agmatine")
428 was monitored over five hours using LC-MS/MS. Similarly, the appearance of the N6-
429 methyladenine signal was assessed in *S. aureus* cultures at 0, 4, 8, 10, and 12 hours with LC-MS.
430 To demonstrate that agmatine concentrations are proportional to microbial load, Muller Hinton
431 Medium was seeded with varying concentrations of *E. coli* (ATCC 25922; 10^3-10^8 CFU/mL) and
432 agmatine levels were measured following a 6-hour incubation period using the Q Exactive™ HF
433 platform. Inhibition of agmatine production by boric acid preservative, at concentrations used in
434 BD Vacutainer Plus Tubes (2.63 mg/mL boric acid, 3.95 mg/mL sodium borate, 1.65 mg/mL
435 sodium formate) was monitored in filter sterilized urine seeded with *E. coli* (three reference strains
436 – MG1665, ATCC 25922, ATCC BAA-196 – and four clinical isolates) over a 24-hour period and
437 analyzed on the Q Exactive™ HF platform.

438 *Blinded performance evaluation of agmatine versus traditional urine analysis pipeline*

439 Mid-stream urine samples for the blinded head-to-head performance evaluation were collected
440 from Alberta Precision Laboratories' standardized urine analysis workflow (described above in
441 *Urine Sample Collection*). These samples were stripped of diagnostic information and assigned a
442 unique identifier prior to their transfer to the analytical team. Following analysis using a clinically
443 adapted metabolomics platform, diagnostic data were un-masked and the results of the quantitative
444 agmatine-based MS approach were scored against the clinical diagnostic laboratory calls, using
445 174 nM as the threshold for UTI-positive samples.
446 Targeted quantitative assays were conducted in two independently blinded trials using slightly
447 differing methods. In trial 1, targeted mass spectrometry was performed to quantify the levels of

448 agmatine in a blinded cohort of 587 urine specimens. This was done following the targeted mass
449 spectrometry workflow described above using spiked in [U-^{13}C]agmatine and SPE sample cleanup.
450 In trial 2, 1,042 urine specimens were analyzed using a simplified dilute and shoot targeted
451 workflow that accurately captures the two target analytes as well as creatinine in a single injection.
452 This approach negates the use of solid phase extraction, and instead, a 1/20 dilution of the sample
453 was directly injected onto the MS following our chromatographic methods described above using
454 a 3.2-minute gradient and external agmatine standard curves were used for quantification.

455 *Data analysis and statistics*

456 Raw mass spectrometry files were converted into .mzXML files via MSConvertGUI
457 (ProteoWizard Tools)[40]. All full scan MS analyses were conducted in MAVEN. MS/MS data were
458 analyzed using Xcalibur 4.0.27.19 software (Thermo Scientific). Untargeted mass spectrometry
459 data were grouped according to co-variance, co-retention and similarity to common
460 adducts/fragments using previously published software developed in R Statistics[41]. Violin plots,
461 ROC curves, and scatter plots were all generated in R Statistics using existing packages, (FUGU-
462 MS, pROC, and vioPlot). A two-tail unequal variance Welch T-test was used to test differences in
463 agmatine and N6-methyladenine levels in culture positive urine samples compared to negative
464 controls. Alpha thresholds for significance were coerced for multiple hypothesis testing via
465 Bonferroni correction

466 **Data availability**

467 All data are available in the main text or the supplementary materials. Raw mass spectrometry data
468 are available from the study team upon request.

469

References

1. Fernández-García, M., Rojo, D., Rey-Stolle, F., García, A. & Barbas, C. Metabolomic-Based Methods in Diagnosis and Monitoring Infection Progression. in *Metabolic Interaction in Infection* (eds. Silvestre, R. & Torrado, E.) 283–315 (Springer International Publishing, Cham, 2018). doi:10.1007/978-3-319-74932-7_7.

2. Satink, H. P. W. M. *et al.* Microbial influences on urinary polyamine excretion. *Clin Chim Acta* **179**, 305–314 (1989).

3. Lussu, M. *et al.* 1H NMR spectroscopy-based metabolomics analysis for the diagnosis of symptomatic E. coli-associated urinary tract infection (UTI). *BMC Microbiol* **17**, 201 (2017).

4. Bower, J. M. & Mulvey, M. A. Polyamine-mediated resistance of uropathogenic Escherichia coli to nitrosative stress. *J Bacteriol* **188**, 928–933 (2006).

5. Puebla-Barragan, S., Renaud, J., Sumarah, M. & Reid, G. Malodorous biogenic amines in Escherichia coli-caused urinary tract infections in women—a metabolomics approach. *Sci Rep* **10**, 9703 (2020).

6. Bouatra, S. *et al.* The Human Urine Metabolome. *PLoS One* **8**, e73076 (2013).

7. Laupland, K. B., Ross, T., Pitout, J. D. D., Church, D. L. & Gregson, D. B. Community-onset urinary tract infections: A population-based assessment. *Infection* **35**, 150–153 (2007).

8. Alberta Precision Laboratories. *Change of Urine Colony Count Format*. https://www.albertahealthservices.ca/assets/wf/lab/if-lab-hp-bulletin-change-of-urine-colony-count-format.pdf (2021).

9. Lu, C.-D. Pathways and regulation of bacterial arginine metabolism and perspectives for obtaining arginine overproducing strains. *Applied Microbiology and Technology* **70**, 261–272 (2006).

10. Mohapatra, S. S. & Biondi, E. G. DNA Methylation in Prokaryotes: Regulation and Function. in *Cellular Ecophysiology of Microbe* (ed. Krell, T.) 1–21 (Springer, Cham, 2017). doi:10.1007/978-3-319-20796-4_23-1.

11. Adaway, J. E., Keevil, B. G. & Owen, L. J. Liquid chromatography tandem mass spectrometry in the clinical laboratory. *Ann Clin Biochem* **52**, 18–38 (2015).

12. Chan, W. W. Urine Cultures. in *Clinical Microbiology Procedures Handbook* (ed. Leber, A. L.) 3.12.1-3.12.33 (ASM Press, Washington, DC, 2016). doi:10.1128/9781555818814.CH3.12.

13. Leis, J. A. *et al.* Choosing Wisely Canada—Top five list in medical microbiology: An official position statement of the Association of Medical Microbiology and Infectious Disease (AMMI) Canada. *JAMMI* **3**, 61–70 (2018).

14. Arndt, T. Urine-creatinine concentration as a marker of urine dilution: reflections using a cohort of 45,000 samples. *Forensic Sci Int* **186**, 48–51 (2009).

508 15. Barr, D. B. *et al.* Urinary Creatinine Concentrations in the U.S. Population: Implications
509 for Urinary Biologic Monitoring Measurements. *Environ Health Perspect* **113**, 192–200
510 (2005).

511 16. Chu, C. M. & Lowder, J. L. Diagnosis and treatment of urinary tract infections across age
512 groups. *Am J Obstet Gynecol* **219**, 40–51 (2018).

513 17. Schappert, S. M. & Rechtsteiner, E. A. Ambulatory medical care utilization estimates for
514 2007. *Vital and Health Stats. 13* 1–38 (2011).

515 18. Wilson, M. L. & Gaido, L. Laboratory diagnosis of urinary tract infections in adult
516 patients. *Clinical Infectious Diseases* **38**, 1150–1158 (2004).

517 19. Holmes, A. H. *et al.* Understanding the mechanisms and drivers of antimicrobial
518 resistance. *The Lancet* **387**, 176–187 (2016).

519 20. Andersson, D. I. & Hughes, D. Microbiological effects of sublethal levels of antibiotics.
520 *Nat Rev Microbiol* **12**, 465–478 (2014).

521 21. Costelloe, C., Metcalfe, C., Lovering, A., Mant, D. & Hay, A. D. Effect of antibiotic
522 prescribing in primary care on antimicrobial resistance in individual patients: systematic
523 review and meta-analysis. *BMJ* **340**, c2096 (2010).

524 22. O'Neill, J. Rapid Diagnostics: Stopping Unnecessary Use of Antibiotics. *Review on*
525 *Antimicrobial Resistance* (2015).

526 23. Waller, T. A., Pantin, S. A. L., Yenior, A. L. & Pujalte, G. G. A. Urinary Tract Infection
527 Antibiotic Resistance in the United States. *Primary Care - Clinics in Office Practice* **45**,
528 455–466 (2018).

529 24. Laxminarayan, R. *et al.* Antibiotic resistance-the need for global solutions. *Lancet Infect*
530 *Dis* **13**, 1057–1098 (2013).

531 25. Maxim, L. D., Niebo, R. & Utell, M. J. Screening tests: A review with examples. *Inhal*
532 *Toxicol* **26**, 811–828 (2014).

533 26. Kitto, K. & Colledge, E. Urinary Tract Infections in Adults. *Family & Community*
534 *Medicine - University of Toronto* 1–2 Preprint at http://thehub.utoronto.ca/family/wp-
535 content/uploads/2018/03/Urinary-Tract-Infections-in-Adults.pdf (2011).

536 27. Flores-Mireles, A. L., Walker, J. N., Caparon, M. & Hultgren, S. J. Urinary tract
537 infections: Epidemiology, mechanisms of infection and treatment options. *Nat Rev*
538 *Microbiol* **13**, 269–284 (2015).

539 28. Jannetto, P. J. & Fitzgerald, R. L. Effective use of mass spectrometry in the clinical
540 laboratory. *Clin Chem* **62**, 92–98 (2016).

541 29. Huisman, H., Wynveen, P., Nichkova, M. & Kellermann, G. Novel ELISAs for screening
542 of the biogenic amines GABA, glycine, β-phenylethylamine, agmatine, and taurine using
543 one derivatization procedure of whole urine samples. *Anal Chem* **82**, 6526–6533 (2010).

30. Semeniuk, H. & Church, D. Evaluation of the Leukocyte Esterase and Nitrite Urine Dipstick Screening Tests for Detection of Bacteriuria in Women with Suspected Uncomplicated Urinary Tract Infections. *J Clin Microbiol* **37**, 3051–3052 (1999).

31. Nicolle, L. E. Asymptomatic bacteriuria: When to screen and when to treat. *Infect Dis Clin North Am* **17**, 367–394 (2003).

32. Dong, X. *et al.* Thermogenic hydrocarbon biodegradation by diverse depth-stratified microbial populations at a Scotian Basin cold seep. *Nat Commun* **11**, 5825 (2020).

33. Mager, L. F. *et al.* Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. *Science (1979)* **369**, 1481–1489 (2020).

34. Rydzak, T. *et al.* Metabolic preference assay for rapid diagnosis of bloodstream infections. *Nat Commun* **13**, 2332 (2022).

35. Groves, R. A. *et al.* Methods for Quantifying the Metabolic Boundary Fluxes of Cell Cultures in Large Cohorts by High-Resolution Hydrophilic Liquid Chromatography Mass Spectrometry. *Anal Chem* **94**, 8874–8882 (2022).

36. Mohammadi, M. *et al.* Microbial containment device: A platform for comprehensive analysis of microbial metabolism without sample preparation. *Front Microbiol* **13**, 1–13 (2022).

37. Mapar, M., Rydzak, T., Groves, R. A. & Lewis, I. A. Biomarker enrichment medium: A defined medium for metabolomic analysis of microbial pathogens. *Front Microbiol* **13**, 657158 (2022).

38. Clasquin, M. F., Melamud, E. & Rabinowitz, J. D. LC-MS Data Processing with MAVEN: A Metabolomic Analysis and Visualization Engine. *Curr Protoc Bioinformatics* **37**, 14.11.1-14.11.23 (2012).

39. Melamud, E., Vastag, L. & Rabinowitz, J. D. Metabolomic analysis and visualization engine for LC–MS data. *Anal Chem* **82**, 9818–9826 (2010).

40. Chambers, M. C. *et al.* A cross-platform toolkit for mass spectrometry and proteomics. *Nat Biotechnol* **30**, 918–920 (2012).

41. R Core Team. R: A Language and Environment for Statistical Computing. Preprint at https://www.r-project.org/ (2019).

Acknowledgments

This work was supported by a Genomics Application Partnership Program award from Genome Canada (10019200), Genome Alberta (10021232), Canadian Institute of Health Research (10020019), and the 2017 Large Scale Applied Research Project competition. This work was made possible in part by a research collaboration agreement with Thermo Fisher Scientific. IAL was

supported by an Alberta Innovates Translational Health Chair (10010625). TR was supported by an Eyes High Postdoctoral Fellowship from the University of Calgary (10011121). S.D.W. was supported in part by an NSERC Undergraduate Summer Research Award. Metabolomics data were acquired at the Calgary Metabolomics Research Facility, which is part of the Alberta Centre for Advanced Diagnostics (ACAD; PrairiesCan RIE #22734) and is supported by the International Microbiome Centre and the Canada Foundation for Innovation (CFI-JELF 34986)

Author Contributions

S.D.W., C.C.Y.C., D.B.G., D.G.B., T.R., and I.A.L. designed and performed the experiments S.D.W., D.B.G., D.G.B., C.C.Y.C., R.A.G., D.B.G., R.A., and T.R. collected and interpreted mass spectrometry data. K.P., N.V.B., and I.A.L. interpreted results wrote the manuscript in consultation with all authors.

Competing Interest Statement

Drs. Lewis, Gregson and Mr. Groves are authors on a patent relating to the use of LC-MS for detecting urinary tract infections. No other competing interests declared.



Figure 1. Discovery of agmatine and N6-methyladenine as UTI biomarkers. (a) LC-MS data were acquired from metabolites predictive of culture-positive (yellow points) and culture-negative (purple points) urine samples. Potential UTI biomarkers were identified (*m/z* 131.1289 and *m/z* 150.0772 shown as example; see inset for chromatogram). **(b)** Predictive UTI biomarkers were ranked according to receiver operating characteristic (ROC) curves. Signal 1 (*m/z* 114.1025) and signal 2 (*m/z* 131.1289) were assigned to agmatine, and signal 3 (*m/z* 150.0771) was assigned to N6-methyladenine. **(c)** Agmatine and **(d)** N6-methyladenine assignments were verified by tandem LC-MS/MS fragmentation patterns observed in a culture-positive urine sample (i, iv), an analytical standard of the target molecule (ii; 250 nM, v; 50 µM), and a standard added to a

607 culture-negative urine sample at the same concentration (iii, vi). Abbreviations: Agm, agmatine;

608 6-MA, N6-methyladenine; Neg, growth-negative urine; Pos, growth-positive urine.

609


a
Total AUC = 0.99
CI = 0.98 – 1.00
Thresh (---) = 0.17 μM
Sensitivity = 0.94
Specificity = 0.97
PPV = 0.96
NPV = 0.95
Urine sample + Internal Standard
(12C-Agm) (13C-Agm)
LC-MS/MS
I12C-Agm / I13C-Agm = [12C-Agm] / [13C-Agm]
Agmatine concentration (μM)
ENT
Mix
Non-ENT
No Growth (N=190)
DCS (N=89)
C. amalonaticus (N=1)
C. braakii (N=2)
C. farmeri (N=1)
C. freundii (N=10)
C. koseri (N=7)
E. aerogenes (N=5)
E. cloacae cplx. (N=18)
E. coli (N=106)
K. oxytoca (N=17)
K. pneumoniae (N=36)
P. mirabilis (N=21)
E. coli & E. faecalis (N=2)
E. coli & non-pathogen(s) (N=6)
E. coli & P. aeruginosa (N=1)
E. faecalis (N=4)
E. faecium (N=1)
C. parapsilosis (N=1)
S. saprophyticus (N=1)
b
Total AUC = 0.89
CI = 0.83 – 0.95
Thresh (---) = 8.3x10³
Sensitivity = 0.91
Specificity = 0.83
PPV = 0.84
NPV = 0.91
STA+AUR
N6-methyladenine Signal Intensity (10⁶)
Negative (N=24)
GBS (N=11)
Candida spp. (N=4)
E. faecalis (N=24)
P. aeruginosa (N= 9)
S. aureus (N=11)
S. saprophyticus (N=10)
A. urinae (N=2)
c
Arg and Agm Signal Intensity (10⁵)
[15N]agmatine
[15N]arginine
ATCC BAA-196
ATCC 25922
MG1665
Time (hours)
6-MA Signal Intensity (10⁶)
N6-methyladenine
ATCC 25923
ATCC 43300
Time (hours)

610

611 **Figure 2. Microbial metabolite signals differentiate *Enterobacterales* and certain non-**
612 ***Enterobacterales* positive urines from controls. (a)** Violin plot of agmatine concentrations in
613 urine samples determined by spike-in of stable isotope-labeled internal standard following SPE
614 (see inset). White dots indicate median values, thick black bars indicate interquartile ranges, and
615 thin black lines indicate 3x interquartile hinge points. **(b)** Violin plot of N6-methyladenine signal
616 intensities from a prospectively collected non-*Enterobacterales* cohort of patient urine samples.
617 **(c)** Three *E. coli* strains grown in sterile urine spiked with [$^{15}N_2$]arginine for eight hours (top)
618 were monitored for [$^{15}N_2$]agmatine production. Two *S. aureus* strains grown in sterile urine for 12
619 hours (bottom) and were monitored for N6-methyladenine production. Abbreviations: Agm,
620 agmatine; AUC, area under curve; CI, confidence interval; Thresh, threshold; PPV, positive
621 predictive value; NPV, negative predictive value; DCS, doubtful clinical significance; Non-ENT,
622 Non-*Enterobacterales*; ENT, *Enterobacterales*; STA, *Staphylococcus* species; AUR, *Aerococcus*
623 *urinae*; Arg, arginine; 6MA, N6-methyladenine; GBS, Group B Streptococci.

624

625



626

627 **Figure 3. Blinded performance trial of clinically adapted metabolomics-based UTI**
628 **diagnostics. (a)** Agmatine concentrations in a blinded cohort of clinical urine samples. Categories
629 on x-axis represent calls from traditional microbiology analysis performed at a regional
630 diagnostic lab. (**b**) Receiver operator curve demonstrating the performance of agmatine as a
631 diagnostic marker for *Enterobacterales* in a blinded, prospective trial. Sensitivity and specificity
632 for 0.17 μM threshold is represented by the yellow dot. Abbreviations: NG, no growth; DCS,
633 doubtful clinical significance; Non-ENT, Non-*Enterobacterales*; ENT, *Enterobacterales*; Mix,
634 polymicrobial cultures containing at least one *Enterobacterales* member; AUC, area under curve;
635 CI, confidence interval; Thresh, threshold; PPV, positive predictive value;NPV, negative
636 predictive value.

637

638

639



640

641 **Figure 4. Creatinine normalized agmatine concentrations in a blinded cohort of urine**
642 **specimens. (a)** Violin plot of agmatine concentrations compared to creatinine normalized
643 agmatine concentrations. **(b)** Receiver operator curves demonstrating the equivalence between
644 detected agmatine levels and creatinine normalized agmatine levels. Sensitivity and specificity
645 calculated for 0.17 μM threshold. Abbreviations: NG, no growth; DCS, doubtful clinical
646 significance; Non-ENT, Non-*Enterobacterales*; ENT, *Enterobacterales*; Mix, polymicrobial
647 cultures containing at least one *Enterobacterales* member; AUC, area under curve.